ClinicalTrials.gg
Drug

Gastric Inhibitory Polypeptide clinical trials

Also written GIP.

Its developmentBy Novo Nordisk, step by step1 company-led study, furthest phase 1: when each phase was reached, its deals, target and what is ahead.
studies test it
17
open now
6
in phase 3
0
first study started
2003

How each study uses Gastric Inhibitory Polypeptide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Gastric Inhibitory Polypeptide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Glucose-dependent Insulinotropic Polypeptide (GIP)
3

Other names

GIP
7
Glucose-Dependent Insulinotropic Polypeptide
2

Studies by the year they started

17 studies that test it; most in 2009 (2)

Studies that test Gastric Inhibitory Polypeptide, by start year
YearStudies
20031
20092
20121
20132
20141
20161
20171
20192
20221
20231
20241
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
7
Phase 2
2
No phase
9

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 1 · Other 16

University Hospital, Gentofte, Copenhagen (3) · Asger Lund, MD (2) · Steno Diabetes Center Copenhagen (2) · David D'Alessio, M.D. (1) · Washington University School of Medicine (1) · University of Nottingham (1) · Rigshospitalet, Denmark (1) · National Institute on Aging (NIA) (1)

Often tested with

Tested in the same studies.

Glucagon-Like Peptide 1 (7) · Alanine (2) · Semaglutide (2) · Incretins (1) · Glimepiride (1) · Xenin 25 (1) · Insulin, Regular, Human (1) · Amino Acids (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test Gastric Inhibitory Polypeptide.

Studies

Open first, then newest update. How each study uses Gastric Inhibitory Polypeptide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 2 — Gastric Inhibitory Polypeptide is usual care or a partner of the new treatment

Codes

What other systems call Gastric Inhibitory Polypeptide · ClinicalTrials.gg INT007544

  • MeSH (NLM) D005749Gastric Inhibitory PolypeptideOne source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.